ESMO 2026 | Emerging EGFR bispecific antibodies and flexible dosing in head and neck cancer
Paul Swiecicki, MD, University of Michigan, Ann Arbor, MI, discusses the upcoming developments in EGFR bispecific antibodies for head and neck cancer, highlighting the the importance of considering overall survival, response rate, and patient quality of life as a composite measure for treatment decisions. Dr Swiecicki also emphasizes the need for flexible dosing regimens to accommodate patients who face challenges in accessing clinic visits. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
This is a very exciting time. We have three major EGFR bispecific antibodies in development, and we really look forward to the phase three studies, which will hopefully come out in the next year or so. And until then, we really don’t know. There will be a lot of studies, as you say, that come out and we’ll be forced to look at the overall survival, response rate, and patient quality of life...
This is a very exciting time. We have three major EGFR bispecific antibodies in development, and we really look forward to the phase three studies, which will hopefully come out in the next year or so. And until then, we really don’t know. There will be a lot of studies, as you say, that come out and we’ll be forced to look at the overall survival, response rate, and patient quality of life. I think all of those, as a single composite measure, will be important to make treatment decisions. And finally, dosing regimens, because many patients, it’s very difficult to come to the clinic. And so hopefully we have many treatments in our armamentarium in the near future. I look forward to all those studies coming out.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
